Read by QxMD icon Read


Charles Edouard Zurstrassen, Luiz Paulo De Oliveira Gireli, Chiang Jeng Tyng, Almir Galvão Vieira Bitencourt, Marcos Duarte Guimarães, Paula Nicole Vieira Barbosa, Aline Cristine Barbosa Santos Cavalcante, João Paulo Matushita Junior, Mauricio Kauark Amoedo, Felipe Jose Coimbra, Rogério Camargo Pinheiro Alves, Rubens Chojniak
AIM: To evaluate the effects of HepaSphere 50-100 μm (Merit Medical) as a doxorubicin carrier and embolization agent for the treatment of hepatocellular carcinoma (HCC). MATERIAL AND METHODS: A prospective analysis of 18 patients recruited from a national cancer center was conducted. This analysis evaluated the efficacy and safety of HepaSphere, as expressed by the treatment response rate (measured by the modified Response Evaluation Criteria in Solid Tumors, mRECIST) and by the prevalence of treatment-related adverse events, respectively...
August 2017: Minimally Invasive Therapy & Allied Technologies: MITAT
Akihiko Seki, Chigusa Shimono
PURPOSE: To evaluate the hemostatic effects of transarterial infusion chemotherapy in addition to embolization (chemoembolization) for advanced primary lung cancer with tumor-related hemoptysis. MATERIALS AND METHODS: Ten consecutive patients with stage IIIB/IV or recurrent primary lung cancer (squamous cell carcinoma in six, adenocarcinoma in four) who underwent chemoembolization for control of hemoptysis were enrolled. At enrollment, five patients were considered refractory and five had contraindications to standard therapies...
September 2017: Japanese Journal of Radiology
Lawrence Bonne, Chris Verslype, Annouschka Laenen, Sandra Cornelissen, Christophe M Deroose, Hans Prenen, Vincent Vandecaveye, Eric Van Cutsem, Geert Maleux
BACKGROUND: The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. PATIENTS AND METHODS: Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50-100 μm Hepasphere/Quadrasphere Microsphere® particles, Merit Medical, South Jordan, Utah, USA) were included in this study...
March 1, 2017: Radiology and Oncology
Yusuke Imai, Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Eiji Takeshita, Masanori Abe, Hiroaki Tanaka, Mie Kurata, Sohei Kitazawa, Yoichi Hiasa
A 58-year-old man was diagnosed with advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT). The tumors were multiple and existed in both lobes. Drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) was performed for the tumors in the left lobe. Embosphere and Hepasphere were selected for embolization of the arterioportal shunt, followed by loaded epirubicin infusion into the left hepatic artery. Computed tomography showed reduction of PVTT. However, liver failure progressed, and the patient died 67 days after DEB-TACE...
March 2017: Radiology Case Reports
Jun-Hui Sun, Guan-Hui Zhou, Yue-Lin Zhang, Chun-Hui Nie, Tan-Yang Zhou, Jing Ai, Tong-Yin Zhu, Wei-Lin Wang, Shu-Sen Zheng
Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for unresectable hepatocellular carcinoma (HCC). The efficacy of conventional TACE (cTACE) in liver metastases is not satisfactory, which might be due to the fact of embolic material used. Recently, as a new type of drug-loading microsphere, HepaSphere has been introduced in China. In this study, there were total 30 patients (18 males and 12 females) with liver cancer underwent embolization with Hepasphere microsphere. And a total of 44 TACE procedures were performed using 50-100μm HepaSphere...
January 17, 2017: Oncotarget
Keita Yamashiro, Astushi Hori, Takeo Yuki, Ryosuke Ohira, Shinichi Hori
Here, we report a case of cholangiocellular carcinoma that was successfully treated with chemotherapy using a selective intra-arterial infusion technique. A 65-year-old man presented to our hospital to obtain a second opinion regarding his disease. The patient was diagnosed with cholangiocellular carcinoma. The giant tumor was located in the porta hepatis. Some small nodules that were considered to be metastatic lesions were also observed in the surroundingarea. The tumor was judged by the primary physician to be too large for surgical treatment...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Thierry de Baere, Stephen Plotkin, Renee Yu, Allison Sutter, Yue Wu, Gregory M Cruise
PURPOSE: To compare in vitro properties of 4 drug-eluting embolic agents loaded with doxorubicin. MATERIALS AND METHODS: DC Bead (100-300 µm), LifePearl (200 µm), HepaSphere (30-60 µm), and Tandem (100 µm) microspheres were loaded with 40 mg/20 mL of doxorubicin per milliliter of microspheres. Loading, elution, diameter changes after loading, changes in the amount of doxorubicin loaded over 2 weeks in storage, and time in suspension were evaluated. RESULTS: All microspheres loaded > 99% doxorubicin within 1 hour...
September 2016: Journal of Vascular and Interventional Radiology: JVIR
Atsuyuki Ikeda, Yumiko Yasuhara, Daizen Hirata, Mari Teramura, Takeharu Nakamura, Yoko Oiwa, Osamu Araki, Hidemasa Azechi, Ryuta Nishitai, Hiroyuki Kokuryu
We report a case of resected hepatocellular carcinomas (HCCs) after drug-eluting bead transarterial chemoembolization (DEB-TACE). A 67-year-old man with alcoholic liver disease was diagnosed with HCCs. Serological markers for hepatitis B and C viruses were negative. Among tumor markers, alpha-fetoprotein was 2.7ng/mL, and protein induced by vitamin K absence II was 868mAU/mL. Two HCCs were detected using dynamic computed tomography: one was 9cm in diameter in S8 and the other was 2cm in diameter in S4. We performed DEB-TACE using HepaSphere(®) and epirubicin...
2016: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
Norifumi Kennoki, Shinichi Hori, Takeo Yuki, Satoshi Sueyoshi, Atsushi Hori
Here, we report the use of trans-arterial chemoembolization for primary lung cancer. The patient was a 56-year-old woman with refractory Stage Ⅳ non-small cell lung cancer who had been treated with repeated systemic chemotherapy. The primary lesion in the right lower lobe was 75 mm in size, with multiple lung metastases. It invaded the right main bronchus and caused severe cough. Radiotherapy was not indicated because of the size and extent of the lesion. During a period of 6 months, chemoembolization of the bilateral bronchial arteries using cisplatin 20 mg, docetaxel 20 mg, and 5-FU 250 mg with HepaSphere (super-absorbent polymer microspheres) was performed 5 times...
November 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fahrettin Kucukay, Serife Badem, Adnan Karan, Mustafa Ozdemir, Riza S Okten, Nilgun I Ozbulbul, Murat B Kucukay, Ipek Unlu, Erdal B Bostanci, Meral Akdogan
PURPOSE: To compare doxorubicin-loaded HepaSphere transarterial chemoembolization versus conventional transarterial chemoembolization in terms of survival, time to recurrence, acute reversible hepatotoxicity, postembolization syndrome, and chemoembolization-related mortality and morbidity. MATERIALS AND METHODS: One hundred twenty-six patients (103 men, 23 women; mean age, 64.3 y) with unresectable hepatocellular carcinoma (HCC) who underwent conventional chemoembolization between January 2007 and March 2011 or drug-eluting embolic (DEE) chemoembolization (after the protocol change) between March 2011 and October 2014 were included in a retrospective analysis...
November 2015: Journal of Vascular and Interventional Radiology: JVIR
Takao Hiraki, Jun Koizumi, Yasuaki Arai, Yasuo Sakurai, Hiromitsu Kumada, Yoshihiro Nambu, Shinichi Hori
PURPOSE: To evaluate the feasibility and safety of transcatheter arterial embolization (TAE) with the use of HepaSphere microspheres for hypervascular tumors. MATERIALS AND METHODS: This was a prospective multicenter open label clinical trial involving six institutions in Japan. TAE was performed with the HepaSphere microspheres for hypervascular tumors in various locations. The endpoint of the study was the feasibility and safety of the procedure. The feasibility and safety were evaluated according to technical success and adverse events, respectively...
August 2015: Japanese Journal of Radiology
Julien Namur, Florentina Pascale, Noboru Maeda, Manon Sterba, Saida Homayra Ghegediban, Valentin Verret, Angelo Paci, Atmane Seck, Keigo Osuga, Michel Wassef, Philippe Reb, Alexandre Laurent
PURPOSE: To compare irinotecan-eluting HepaSphere (BioSphere Medical, Roissy-en-France, France) and DC Bead (Biocompatibles UK Ltd, London, United Kingdom) embolization microspheres for distribution in tumors, release properties, tolerance, and antitumor effects in a model of liver metastases in the rabbit. MATERIALS AND METHODS: Multiple liver tumors were created by injection of a VX2 cell suspension in the portal vein of rabbits. After 2 weeks, embolization of the proper hepatic artery was performed with a fixed volume of bland HepaSphere (n = 5), irinotecan-loaded HepaSphere (n = 6), or irinotecan-loaded DC Bead (n = 5) microspheres...
July 2015: Journal of Vascular and Interventional Radiology: JVIR
Yì-Xiáng J Wáng, Thierry De Baere, Jean-Marc Idée, Sébastien Ballet
Transarterial chemoembolization (TACE) is a form of intra-arterial catheter-based chemotherapy that selectively delivers high doses of cytotoxic drug to the tumor bed combining with the effect of ischemic necrosis induced by arterial embolization. Chemoembolization and radioembolization are at the core of the treatment of liver hepatocellular carcinoma (HCC) patients who cannot receive potentially curative therapies such as transplantation, resection or percutaneous ablation. TACE for liver cancer has been proven to be useful in local tumor control, to prevent tumor progression, prolong patients' life and control patient symptoms...
April 2015: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
Katerina Malagari, Maria Pomoni, Hippokratis Moschouris, Alexios Kelekis, Angelos Charokopakis, Evanthia Bouma, Themistoklis Spyridopoulos, Achilles Chatziioannou, Vlasios Sotirchos, Theodoros Karampelas, Constantin Tamvakopoulos, Dimitrios Filippiadis, Enangelos Karagiannis, Athanasios Marinis, John Koskinas, Dimitrios A Kelekis
BACKGROUND: This study examined the safety, pharmacokinetics, and efficacy of transarterial chemoembolization of hepatocellular carcinoma (HCC) using a newly developed size of a superabsorbent polymer drug-eluting embolic material. METHODS: Forty-five patients with documented HCC (Child-Pugh score A/B: 55.5 %/44.5 %) were embolized with HepaSphere microspheres 30-60 μm with escalation of lesion, dose, and frequency of re-embolization. Local response was evaluated with modified response evaluation criteria in solid tumors (mRECIST)...
February 2014: Cardiovascular and Interventional Radiology
Peter Huppert, Thorsten Wenzel, Hubertus Wietholtz
PURPOSE: This prospective study evaluated the effectiveness and safety of TACE using irinotecan loaded superabsorbent polymer (SAP) microspheres for treatment of colorectal cancer liver metastases (CCLM) in a salvage setting of patients. METHODS: A total of 71 TACE procedures were performed in 29 patients with liver only or liver-dominant CCLM. In all patients, systemic chemotherapy before TACE had failed. Two hundred milligrams of irinotecan were loaded into 50-100 mg of SAP microspheres (HepaSphere™ Microspheres) considering tumor size and vascularization...
February 2014: Cardiovascular and Interventional Radiology
Cristina Sottani, Guido Poggi, Fabio Melchiorre, Benedetta Montagna, Claudio Minoia
A sensitive, selective, accurate and precise method for simultaneous quantification of doxorubicin (DOX) and doxorubicinol (DOXol) in human plasma of patients diagnosed as having intermediate stage unresectable hepatocellular carcinoma (HCC) was developed. The method was based on electrospray tandem mass spectrometry in selected reaction monitoring mode. DOX, DOXol and trofosfamide, an internal standard, were extracted from plasma by using a simple solid phase extraction (SPE) procedure after the addition of 0...
February 1, 2013: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Magdalena Jarząbek, Tomasz Jargiełło, Andrzej Wolski, Paweł Poluha, Małgorzata Szczerbo-Trojanowska
BACKGROUND: Only 10 to 20% of patients with hepatic metastases qualify for radical resection of their lesions. The treatment issue among the rest of patients is a small clinical response to overall chemiotherapy and the frequent inability to treat patients with percutaneous thermoablation. In the latter circumstance, parallel to the radical surgery, the reason is the size of the lesion or lack of access to it. MATERIAL/METHODS: 15 patients with hepatic metastases, who had been rejected from consideration of radical resection and thermoablation were subjected to chemoembolization of the proper hepatic artery branches...
July 2011: Polish Journal of Radiology
Cristina Sottani, Guido Poggi, Pietro Quaretti, Mario Regazzi, Benedetta Montagna, Erica Quaquarini, Marcello Imbriani, Emanuela Leoni, Pamela Di Cesare, Alberto Riccardi, Giovanni Bernardo, Claudio Minoia
AIM: The purpose of this study was the pharmacokinetic (PK) profile assessment in the serum of patients affected by hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) with drug-eluting beads. PATIENTS AND METHODS: This study included 20 patients, 12 treated with DC Bead® and 8 with HepaSphere Microsphere®, preloaded with epirubicin. No patient randomization was used for the inclusion in one group or in the other. Peripheral blood samples were obtained from all patients after the treatment, until 24 hours past the procedure...
May 2012: Anticancer Research
C Damiano Gadaleta, Girolamo Ranieri
The liver is the primary site of metastases for many malignancies. Gastrointestinal cancers are especially prone to spread to the liver and other tumours, as breast cancer and melanoma often spread to the liver. On the other hand, hepatocellular cancer (HCC) is the fifth most common malignancy in the world due to its common etiology from chronic liver damage caused by hepatitis or cirrhosis. Treatments of liver tumours vary according to histology and liver invasion and until now trans-arterial chemoembolization (TACE) has represented a main approach in the therapy of liver tumours...
October 2011: Critical Reviews in Oncology/hematology
Akihiko Seki, Shinich Hori, Kazuya Kobayashi, Seizi Narumiya
PURPOSE: To evaluate the safety, clinical outcomes, and hepatic artery damage after transcatheter arterial chemoembolization (TACE) with epirubicin-loaded superabsorbent polymer microspheres (ELM-TACE) in patients with hepatocellular carcinoma (HCC) in a single center in Japan. MATERIALS AND METHODS: This embolic agent is the original form of microspheres, which has the same composition and nature as HepaSpheres. Between May 2007 and June 2009, 135 patients with unresectable HCC who underwent ELM-TACE were enrolled...
June 2011: Cardiovascular and Interventional Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"